REGENXBIO reports Q3 2025 net loss $61.9M; pipeline advances with key milestones

REGENXBIO Inc.

2025-Q3 EPS reported -$2.46 vs consensus -$1.33 ▼ miss (-84.7%)

Net loss $61.9M ($1.20/sh) vs $59.6M ($1.17/sh) in Q3 2024; revenue $29.7M (+23% YoY).
Cash, equivalents $302M as of Sep 30, 2025; cash runway into early 2027.
RGX-202 Duchenne pivotal enrollment complete (n=30); topline early Q2 2026, BLA mid-2026.
RGX-121 (MPS II) PDUFA date Feb 8, 2026; CSF biomarker reduction >80% sustained at 1 year.
Sura-vec wet AMD pivotal enrollment complete (n=1,200+); topline Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.